Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.63 |
| ▸ | PPARG | P37231 | 5/20 | 0.63 |
| ▸ | LPL | P06858 | 2/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693068 | 1.00 | PPARA (0.63) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL9819438 | 1.00 | PPARA (0.63) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL27830388 | 1.00 | PPARA (0.63) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL28547948 | 1.00 | PPARA (0.63) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL9303918 | 0.98 | PPARA (0.61) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL23085167 | 0.95 | PPARA (0.62) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL29959530 | 0.95 | PPARA (0.62) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL2874471 | 0.95 | PPARA (0.62) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL10624215 | 0.95 | PPARA (0.62) | PPARAPPARGLPLLIPGCETP | |
| SCHEMBL11508066 | 0.93 | PPARA (0.61) | PPARAPPARGLPLLIPGCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326091-A1 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-16 | — | — | US | claimed |
| US-9750711-B2 | Low dose oral pharmaceutical composition of isotretinoin | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-09-05 | — | — | US | claimed |
| EP-3200877-A1 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | Sun Pharmaceutical Industries Ltd (IN) | 2017-08-09 | — | — | EP | claimed |
| US-20170165218-A1 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-15 | — | — | US | claimed |
| US-20160128962-A1 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-12 | — | — | US | claimed |
| WO-2016051288-A1 | LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-04-07 | — | — | WO | claimed |
| EP-1565136-B1 | COMPOSITIONS FOR TRANSDERMAL OXYBUTYNIN THERAPY | WATSON PHARMACEUTICALS INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2612629-A1 | Compositions for transdermal oxybutynin therapy | Watson Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | claimed |
| US-RE41134-E1 | Slow release vehicles for minimizing skin irritancy of topical compositions | ALYZAN, INC. (US) | 2010-02-16 | — | — | US | claimed |
| EP-0970990-B1 | Colored polyester thermoplastic materials comprised of poly(oxyalkylenated) compounds as colorants and specific surfactants as diluents | MILLIKEN & CO (US) | 2004-03-31 | — | — | EP | claimed |
| US-5721275-A | STABLE AQUEOUS RETINOID COMPOSITION CONTAINING HIGH MOLECULAR WEIGHT POLYACRYLIC ACID NEUTRALIZED TO FORM GEL, ANTIOXIDANT | ALYZAN, INC. | 1998-02-24 | — | — | US | claimed |
| EP-0481007-B1 | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids | BAZZANO GAIL S (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0481007-A4 | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS | — | 1992-07-22 | — | — | EP | claimed |
| EP-0481007-A1 | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS. | BAZZANO GAIL S (US) | 1992-04-22 | — | — | EP | claimed |
| WO-1990014833-A1 | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS | BAZZANO GAIL S (US) | 1990-12-13 | — | — | WO | claimed |
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | ADIMABIO LLC (US) | 2023-08-10 | — | — | US | disclosed |
| EP-4181908-A2 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | Adimabio LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-5128329-A | Fenitrothion, sorbitan monooleate, xanthan gum | SUMITOMO CORPORATION (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0481007-A1 | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS. | BAZZANO GAIL S (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1990014833-A1 | SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS | BAZZANO GAIL S (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | CACNA1G, CACNA1I, CACNG2 | PPARA 1622/4885PPARG 1150/4885LPL 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.